The initial success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies heavily reliant on off-patent versions presents a uncertain picture. Although early earnings were impressive, the cessation of patents and the rise of discounted alternatives have eroded the customer base. Consequently, a thorough evaluation